Advertisement

Topics

British Biotech Gets PRIME Designation for its Brittle Bones Drug

04:22 EST 13 Nov 2017 | Labiotech.eu

The EMA has awarded PRIME Designation to Mereo BioPharma’s osteogenesis imperfecta drug, a condition for which there is no treatment on the market. Mereo acquires, develops and commercializes therapies for patients with rare diseases. The company’s portfolio contains four clinical‑stage ...

This awesome article British Biotech Gets PRIME Designation for its Brittle Bones Drug appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)

Original Article: British Biotech Gets PRIME Designation for its Brittle Bones Drug

NEXT ARTICLE

More From BioPortfolio on "British Biotech Gets PRIME Designation for its Brittle Bones Drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...